Literature DB >> 9887056

Roles for C-X-C chemokines and C5a in lung injury after hindlimb ischemia-reperfusion.

N M Bless1, R L Warner, V A Padgaonkar, A B Lentsch, B J Czermak, H Schmal, H P Friedl, P A Ward.   

Abstract

We evaluated the roles of the C-X-C chemokines cytokine-induced neutrophil chemoattractant (CINC) and macrophage inflammatory protein-2 (MIP-2) as well as the complement activation product C5a in development of lung injury after hindlimb ischemia-reperfusion in rats. During reperfusion, CD11b and CD18, but not CD11a, were upregulated on neutrophils [bronchoalveolar lavage (BAL) and blood] and lung macrophages. BAL levels of CINC and MIP-2 were increased during the ischemic and reperfusion periods. Treatment with either anti-CINC or anti-MIP-2 IgG significantly reduced lung vascular permeability and decreased lung myeloperoxidase content by 93 and 68%, respectively (P < 0.05). During the same period, there were significant increases in serum C5a-related neutrophil chemotactic activity. Treatment with anti-C5a decreased lung vascular permeability, lung myeloperoxidase, and BAL CINC by 51, 58, and 23%, respectively (P < 0.05). The data suggest that the C-X-C chemokines CINC and MIP-2 as well as the complement activation product C5a are required for lung neutrophil recruitment and full induction of lung injury after hindlimb ischemia-reperfusion in rats.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9887056     DOI: 10.1152/ajplung.1999.276.1.L57

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  14 in total

1.  C5a-regulated CCAAT/enhancer-binding proteins β and δ are essential in Fcγ receptor-mediated inflammatory cytokine and chemokine production in macrophages.

Authors:  Chunguang Yan; Mei Zhu; Jennifer Staiger; Peter F Johnson; Hongwei Gao
Journal:  J Biol Chem       Date:  2011-12-06       Impact factor: 5.157

Review 2.  Mechanisms and mediators of lung injury after acute kidney injury.

Authors:  Sarah Faubel; Charles L Edelstein
Journal:  Nat Rev Nephrol       Date:  2015-10-06       Impact factor: 28.314

3.  Macrophages mediate lung inflammation in a mouse model of ischemic acute kidney injury.

Authors:  Christopher Altmann; Ana Andres-Hernando; Rachel H McMahan; Nilesh Ahuja; Zhibin He; Chris J Rivard; Charles Louis Edelstein; Lea Barthel; William J Janssen; Sarah Faubel
Journal:  Am J Physiol Renal Physiol       Date:  2011-11-23

Review 4.  Ischemia/Reperfusion.

Authors:  Theodore Kalogeris; Christopher P Baines; Maike Krenz; Ronald J Korthuis
Journal:  Compr Physiol       Date:  2016-12-06       Impact factor: 9.090

5.  Neutralization of Gro alpha and macrophage inflammatory protein-2 attenuates renal ischemia/reperfusion injury.

Authors:  M Miura; X Fu; Q W Zhang; D G Remick; R L Fairchild
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

6.  Ulex europaeus agglutinin II (UEA-II) is a novel, potent inhibitor of complement activation.

Authors:  R Lekowski; C D Collard; W R Reenstra; G L Stahl
Journal:  Protein Sci       Date:  2001-02       Impact factor: 6.725

7.  A novel method for isolation of neutrophils from murine blood using negative immunomagnetic separation.

Authors:  M J Cotter; K E Norman; P G Hellewell; V C Ridger
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

8.  Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage.

Authors:  M Fung; M Lu; H Fure; W Sun; C Sun; N Y Shi; Y Dou; J Su; X Swanson; T E Mollnes
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

9.  Role for the alternative complement pathway in ischemia/reperfusion injury.

Authors:  Gregory L Stahl; Yuanyuan Xu; Liming Hao; Mendy Miller; Jon A Buras; Michael Fung; Hui Zhao
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

Review 10.  Mesenchymal Stem Cell Transplantation for Ischemic Diseases: Mechanisms and Challenges.

Authors:  Thi-Tuong Van Nguyen; Ngoc Bich Vu; Phuc Van Pham
Journal:  Tissue Eng Regen Med       Date:  2021-04-21       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.